查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2158022

氨力農注射劑市場：全球市場預測，2026-2032年

Amrinone for Injection Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，氨利酮注射劑市場將成長至 3.3583 億美元，複合年成長率為 5.23%。

主要市場統計數據
基準年 2025 2.3494億美元
預計年份：2026年 2.4744億美元
預測年份 2032 3.3583億美元
複合年成長率 (%) 5.23%

氨力農注射劑：概述

氨力農注射液是一種靜脈注射的正性肌力藥物和血管擴張劑，傳統上用於短期治療嚴重心臟衰竭和某些低心摶出量心臟病。其臨床意義取決於治療環境、當地核准情況、醫療規範以及替代正性肌力藥物和機械循環支持裝置的可用性。因此，評估應著重於證據、安全性監測、供應連續性和適當的患者選擇，而不是假定其廣泛應用。

在臨床實踐中，藥物的使用正朝著嚴格定義的方向發展。

當前情況受到人們對循證急性心臟護理、血流動力學監測和風險管理日益成長的關注的影響。臨床醫生擴大將正性肌力藥物治療與其他替代方案（包括其他藥物治療和器械輔助治療）進行比較，同時考慮心律不整、低血壓、血小板減少性疾病和器官功能受限的風險。由於監管情況和產品供應情況因地區而異，藥品目錄管理和醫療機構的專業水平成為決定患者能否獲得該藥物的關鍵因素。

人工智慧可以提高安全性和正確使用方法。

人工智慧可以作為氨力農相關治療中專家判斷的補充，但不能取代專家判斷。其潛在應用包括識別有血流動力學惡化風險的患者、整合實驗室和監測數據、檢測不利事件模式以及改進藥物配對流程。負責任的實施需要臨床檢驗的模型、透明的升級規則、安全的資料處理以及持續的偏差和誤報審查。人工智慧應始終作為床邊評估和既定處方方案的輔助工具。

區域差異可概括為：醫療服務可近性、證據和重症監護能力。

北美地區雖然心臟護理基礎設施整體完善，但其醫療服務可近性受到處方藥目錄製定、藥品附加檔要求以及與其他療法競爭的限制。歐洲的醫療實踐受到國家和歐洲法規結構、醫療技術評估以及對藥物安全監測的高期望的影響。亞太地區的醫療服務可近性、生產能力和重症監護能力因市場而異。拉丁美洲的採購可靠性和專科醫生的可近性可能存在差異。中東地區三級醫療的集中化和對進口的依賴影響了醫療服務的可近性，而非洲則常常面臨重症監護能力、診斷能力和藥品持續供應方面的更廣泛限制。在所有地區，經本地檢驗的監管和採購資料至關重要。

每個經濟和安全群體都有不同的協調需求。

東協成員國可從加強區域合作，提升藥品註冊、供應連續性和重症監護訓練水準方面獲益。同時，金磚國家在國內生產、監管成熟度和醫院容量方面存在顯著差異。歐盟體系採用通用的法規結構，但採購和報銷方面的決策權仍由各成員國自行決定。七國集團（G7）成員國通常擁有先進的藥物警戒和重症監護體系，但藥品取得政策和處方藥清單在很大程度上仍因國而異。海灣合作理事會（GCC）成員國雖然通常擁有先進的三級醫療設施，但仍依賴協調的採購和進口。北約成員國雖然未必代表聯盟內統一的臨床實踐，但其民用和作戰醫療環境中都需要健全的醫療物流和連續性計畫。

根據各國的具體情況，在做出聘用決定之前，有必要進行現場檢驗。

在澳洲、加拿大、法國、德國、義大利、日本、韓國、英國、英國和美國，必須核實國內核准情況、醫院處方藥清單、臨床指引和供應情況。在巴西、中國、印度、墨西哥和俄羅斯，註冊途徑、公共和私人採購、國內生產以及專家取得途徑等方面可能存在差異。針對特定國家的評估應審查現有產品標籤、已批准的適應症、藥物安全監測要求、進口或分銷條件以及替代療法的可近性。這些因素可能對合理用藥產生重大影響，不應僅根據其所屬地區或經濟集團來推斷。

優先考慮管治、供應彈性和臨床醫生準備。

產業領導者必須掌握最新的監管文件，並了解各國具體的藥品供應情況，才能推進藥品取得和採購計畫。醫院和醫療系統應充分利用涵蓋患者選擇、劑量、輸液監測、禁忌症、不利事件管理和過渡計畫的多學科方案。供應策略應包括經認證的供應商、緊急庫存管理規則、品質文件以及供不應求預警監測。證據生成應側重於具有臨床意義的結果和真實臨床實踐中的安全性，人工智慧計劃應從有限的、可審計的應用案例開始，並輔以臨床醫生監督和網路安全措施。

調查方法：依管轄區進行實證評估。

本執行摘要採用結構化審查架構對氨力農注射液進行評估，重點關注檢驗的監管資訊、臨床文獻、藥物安全監測資訊來源、醫療指南、採購文件以及公開的醫療系統資料。研究結果按臨床實踐、技術、地區、經濟集團和國家/地區進行分類。由於核准情況、供應情況和標準可能發生變化，因此在做出任何操作決策之前，應根據當前國家監管機構、醫院處方集、官方短缺通知和同行評審的證據來檢驗結論。本摘要未使用任何市場估計、預測、市場規模、市場佔有率或預測資料。

合理使用取決於證據、基礎設施和當地條件。

氨力農注射液在急性心血管疾病的治療中佔據獨特地位，其治療策略很大程度上取決於患者的病情、監測能力、替代療法以及相關司法管轄區的要求。最重要的優先事項包括嚴格的管治、可靠的供應、專業的培訓、透明的安全監測以及精心管理的數位支援。管理者應將現場檢驗和持續的臨床審查作為所有關於藥物取得、採購或實施決策的先決條件。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 氨力農注射劑市場：依劑型分類

  • 凍乾粉
    • 墨水匣
    • 管瓶
  • 注射液

第8章：氨力農注射劑市場：依適應症分類

  • 急性心臟衰竭
  • 心源性休克
  • 慢性心臟衰竭
    • 舒張功能障礙
    • 收縮功能障礙

第9章：氨力農注射劑市場：依最終用戶分類

  • 門診部
  • 醫院
    • 公立醫院
    • 私立醫院
  • 專科診所
    • 心臟診所
    • 循環系統中心

第10章：氨力農注射劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第11章 氨力農注射劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第12章 氨力農注射劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第13章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第14章：公司簡介

  • Alkem Laboratories Ltd.
  • Amneal Pharmaceuticals LLC
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Hospira, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Macarthur Medical Supply Pty Ltd
  • Merck Sharp & Dohme Corp.
  • Mylan NV
  • Mylan Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pfizer Ireland Pharmaceuticals
  • Recipharm AB
  • Roche Holding AG
  • Sandoz International GmbH
  • Sanofi-Aventis Deutschland GmbH
  • Siegfried Holding AG
  • SteriMax, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited

第15章 主要專家

Product Code: MRR-4654A89DA778

The Amrinone for Injection Market is projected to grow by USD 335.83 million at a CAGR of 5.23% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 234.94 million
Estimated Year [2026] USD 247.44 million
Forecast Year [2032] USD 335.83 million
CAGR (%) 5.23%

Amrinone for Injection: Executive Overview

Amrinone for injection is an intravenous inotropic and vasodilator therapy historically associated with short-term management of severe heart-failure states and selected low-output cardiac conditions. Its clinical relevance depends on the treatment setting, local approval status, institutional protocols, and the availability of alternative inotropes and mechanical circulatory support. Assessment should therefore focus on evidence, safety monitoring, procurement continuity, and appropriate patient selection rather than broad utilization assumptions.

Clinical Practice Is Shifting Toward Tightly Defined Use

The landscape is shaped by heightened attention to evidence-based acute cardiac care, hemodynamic monitoring, and risk management. Clinicians increasingly evaluate inotropic therapy against alternatives, including other pharmacologic agents and device-supported interventions, while considering arrhythmia risk, hypotension, thrombocytopenia, and organ-function constraints. Regulatory status and product availability also vary across jurisdictions, making formulary governance and institutional expertise important determinants of access.

Artificial Intelligence Can Strengthen Safety and Stewardship

Artificial intelligence can support, but not replace, specialist judgment in amrinone-related care. Potential applications include identifying patients at risk of hemodynamic deterioration, integrating laboratory and monitoring data, detecting adverse-event patterns, and improving medication-reconciliation workflows. Responsible deployment requires clinically validated models, transparent escalation rules, secure data handling, and continuous review for bias and false alarms. AI should remain an adjunct to bedside assessment and established prescribing protocols.

Regional Differences Center on Access, Evidence, and Critical-Care Capacity

North America generally benefits from advanced cardiac-care infrastructure, but use is constrained by formulary decisions, labeling requirements, and competition from alternative therapies. Europe's practice is influenced by national and European regulatory frameworks, health-technology assessment, and strong pharmacovigilance expectations. Asia-Pacific presents varied access, manufacturing, and intensive-care capabilities across markets. Latin America may experience differences in procurement reliability and specialist availability. In the Middle East, tertiary-care concentration and import dependence can shape access, while Africa often faces wider constraints in critical-care capacity, diagnostics, and continuous medicine supply. Across all regions, locally verified regulatory and procurement data are essential.

Economic and Security Groups Have Distinct Coordination Needs

ASEAN members may benefit from stronger regional approaches to registration, supply continuity, and critical-care training, while BRICS economies span substantial differences in domestic production, regulatory maturity, and hospital capability. European Union systems operate within shared regulatory structures but retain national purchasing and reimbursement decisions. G7 countries generally have sophisticated pharmacovigilance and intensive-care systems, although access and formulary policies remain nationally determined. GCC states often combine advanced tertiary facilities with reliance on coordinated procurement and imports. NATO members require resilient medical logistics and continuity planning for civilian and operational healthcare settings, without implying uniform clinical practice across the alliance.

Country Contexts Require Local Verification Before Adoption Decisions

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States require review of national authorization, hospital formularies, clinical guidance, and supply status. Brazil, China, India, Mexico, and Russia may show additional variation in registration pathways, public and private procurement, domestic manufacturing, and specialist access. Country-level assessment should verify the current product label, approved indications, pharmacovigilance requirements, import or distribution conditions, and availability of alternative therapies. These factors can materially influence responsible use and should not be inferred solely from regional or economic-group membership.

Prioritize Governance, Supply Resilience, and Clinician Readiness

Industry leaders should maintain current regulatory dossiers and map country-specific availability before pursuing access or procurement initiatives. Hospitals and health systems should use multidisciplinary protocols covering patient selection, dosing, infusion monitoring, contraindications, adverse-event response, and transition planning. Supply strategies should include qualified suppliers, contingency inventory rules, quality documentation, and early-warning monitoring for shortages. Evidence generation should focus on clinically meaningful outcomes and real-world safety, while AI initiatives should begin with narrow, auditable use cases supported by clinician oversight and cybersecurity controls.

Methodology: Evidence-Based, Jurisdiction-Specific Assessment

This executive summary uses a structured review framework for amrinone for injection, emphasizing verified regulatory information, clinical literature, pharmacovigilance sources, institutional guidance, procurement documentation, and publicly available health-system materials. Findings are organized across clinical practice, technology, regions, economic groups, and countries. Because authorization, availability, and standards can change, conclusions should be validated against current national regulators, hospital formularies, official shortage notices, and peer-reviewed evidence before operational decisions are made. No market estimates, market sizing, market shares, or forecasts are used.

Responsible Use Depends on Evidence, Infrastructure, and Local Context

Amrinone for injection occupies a specialized position in acute cardiovascular care, where treatment decisions are highly dependent on patient condition, monitoring capability, alternatives, and jurisdictional requirements. The most durable priorities are rigorous governance, reliable supply, specialist training, transparent safety surveillance, and carefully controlled digital support. Leaders should treat local verification and continuous clinical review as prerequisites for any access, procurement, or implementation decision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Amrinone for Injection Market, by Dosage Form

  • 7.1. Introduction
  • 7.2. Lyophilized Powder
    • 7.2.1. Cartridge
    • 7.2.2. Vial
  • 7.3. Solution For Injection

8. Amrinone for Injection Market, by Indication

  • 8.1. Introduction
  • 8.2. Acute Heart Failure
  • 8.3. Cardiogenic Shock
  • 8.4. Chronic Heart Failure
    • 8.4.1. Diastolic Dysfunction
    • 8.4.2. Systolic Dysfunction

9. Amrinone for Injection Market, by End User

  • 9.1. Introduction
  • 9.2. Ambulatory Care Centers
  • 9.3. Hospitals
    • 9.3.1. Government Hospitals
    • 9.3.2. Private Hospitals
  • 9.4. Specialty Clinics
    • 9.4.1. Cardiac Clinics
    • 9.4.2. Cardiology Centers

10. Amrinone for Injection Market, by Region

  • 10.1. Introduction
  • 10.2. Asia-Pacific
  • 10.3. North America
  • 10.4. Latin America
  • 10.5. Europe
  • 10.6. Middle East
  • 10.7. Africa

11. Amrinone for Injection Market, by Group

  • 11.1. Introduction
  • 11.2. ASEAN
  • 11.3. GCC
  • 11.4. European Union
  • 11.5. BRICS
  • 11.6. G7
  • 11.7. NATO

12. Amrinone for Injection Market, by Country

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. United Kingdom
  • 12.7. Germany
  • 12.8. France
  • 12.9. Russia
  • 12.10. Italy
  • 12.11. Spain
  • 12.12. China
  • 12.13. India
  • 12.14. Japan
  • 12.15. Australia
  • 12.16. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2025
  • 13.2. Market Concentration Analysis, 2025
    • 13.2.1. Concentration Ratio (CR)
    • 13.2.2. Herfindahl Hirschman Index (HHI)
  • 13.3. Recent Developments & Impact Analysis, 2025
  • 13.4. Product Portfolio Analysis, 2025
  • 13.5. Benchmarking Analysis, 2025

14. Company Profiles

  • 14.1. Alkem Laboratories Ltd.
  • 14.2. Amneal Pharmaceuticals LLC
  • 14.3. AstraZeneca PLC
  • 14.4. Baxter International Inc.
  • 14.5. Bayer AG
  • 14.6. Boehringer Ingelheim International GmbH
  • 14.7. Cipla Limited
  • 14.8. Dr. Reddy's Laboratories Ltd.
  • 14.9. Eli Lilly and Company
  • 14.10. Endo International plc
  • 14.11. Fresenius Kabi AG
  • 14.12. GlaxoSmithKline plc
  • 14.13. Hospira, Inc.
  • 14.14. Johnson & Johnson Services, Inc.
  • 14.15. Lupin Limited
  • 14.16. Macarthur Medical Supply Pty Ltd
  • 14.17. Merck Sharp & Dohme Corp.
  • 14.18. Mylan N.V.
  • 14.19. Mylan Pharmaceuticals Inc.
  • 14.20. Novartis AG
  • 14.21. Pfizer Inc.
  • 14.22. Pfizer Ireland Pharmaceuticals
  • 14.23. Recipharm AB
  • 14.24. Roche Holding AG
  • 14.25. Sandoz International GmbH
  • 14.26. Sanofi-Aventis Deutschland GmbH
  • 14.27. Siegfried Holding AG
  • 14.28. SteriMax, Inc.
  • 14.29. Sun Pharmaceutical Industries Ltd.
  • 14.30. Takeda Pharmaceutical Company Limited
  • 14.31. Teva Pharmaceutical Industries Ltd.
  • 14.32. Zydus Lifesciences Limited

15. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Amrinone for Injection Market, Years Considered for the Study
  • FIGURE 2. Global Amrinone for Injection Market, Research Design
  • FIGURE 3. Global Amrinone for Injection Market, Research Framework
  • FIGURE 4. Global Amrinone for Injection Market, Data Triangulation
  • FIGURE 5. Global Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Amrinone for Injection Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 7. Global Amrinone for Injection Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Amrinone for Injection Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 9. Global Amrinone for Injection Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Amrinone for Injection Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 11. Global Amrinone for Injection Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Amrinone for Injection Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 13. Global Amrinone for Injection Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Amrinone for Injection Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 15. Global Amrinone for Injection Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 16. Global Amrinone for Injection Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Amrinone for Injection Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Amrinone for Injection Market Segmentation & Coverage
  • TABLE 2. Global Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 4. Global Lyophilized Powder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Lyophilized Powder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Lyophilized Powder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Cartridge Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Cartridge Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Cartridge Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Solution For Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Solution For Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Solution For Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 17. Global Acute Heart Failure Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Acute Heart Failure Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Acute Heart Failure Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Cardiogenic Shock Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Cardiogenic Shock Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Cardiogenic Shock Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Chronic Heart Failure Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Chronic Heart Failure Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Chronic Heart Failure Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Diastolic Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Diastolic Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Diastolic Dysfunction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Systolic Dysfunction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Systolic Dysfunction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Systolic Dysfunction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 33. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global Government Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Government Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Government Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 43. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 44. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 45. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Cardiac Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Cardiac Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Cardiac Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Cardiology Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Cardiology Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Cardiology Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global Amrinone for Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. Asia-Pacific Amrinone for Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Asia-Pacific Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 57. Asia-Pacific Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 58. Asia-Pacific Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 59. Asia-Pacific Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 60. Asia-Pacific Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 61. Asia-Pacific Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 62. Asia-Pacific Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 63. North America Amrinone for Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. North America Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 65. North America Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 66. North America Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 67. North America Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 68. North America Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 69. North America Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 70. North America Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 71. Latin America Amrinone for Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Latin America Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 73. Latin America Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 74. Latin America Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 75. Latin America Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 76. Latin America Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 77. Latin America Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 78. Latin America Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 79. Europe Amrinone for Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Europe Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 81. Europe Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 82. Europe Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 83. Europe Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 84. Europe Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 85. Europe Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 86. Europe Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 87. Middle East Amrinone for Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Middle East Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 89. Middle East Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 90. Middle East Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 91. Middle East Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 92. Middle East Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 93. Middle East Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 94. Middle East Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 95. Africa Amrinone for Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Africa Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 97. Africa Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 98. Africa Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 99. Africa Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 100. Africa Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 101. Africa Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 102. Africa Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 103. Global Amrinone for Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 104. ASEAN Amrinone for Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 105. ASEAN Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 106. ASEAN Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 107. ASEAN Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 108. ASEAN Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 109. ASEAN Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 110. ASEAN Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 111. ASEAN Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 112. GCC Amrinone for Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 113. GCC Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 114. GCC Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 115. GCC Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 116. GCC Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 117. GCC Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 118. GCC Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 119. GCC Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 120. European Union Amrinone for Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 121. European Union Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 122. European Union Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 123. European Union Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 124. European Union Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 125. European Union Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 126. European Union Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 127. European Union Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 128. BRICS Amrinone for Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 129. BRICS Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 130. BRICS Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 131. BRICS Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 132. BRICS Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 133. BRICS Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 134. BRICS Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 135. BRICS Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 136. G7 Amrinone for Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. G7 Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 138. G7 Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 139. G7 Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 140. G7 Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 141. G7 Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 142. G7 Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 143. G7 Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 144. NATO Amrinone for Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 145. NATO Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 146. NATO Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 147. NATO Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 148. NATO Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 149. NATO Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 150. NATO Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 151. NATO Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 152. Global Amrinone for Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 153. United States Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 154. United States Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 155. United States Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 156. United States Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 157. United States Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 158. United States Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 159. United States Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 160. United States Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 161. Canada Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 162. Canada Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 163. Canada Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 164. Canada Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 165. Canada Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 166. Canada Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 167. Canada Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 168. Canada Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 169. Mexico Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 170. Mexico Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 171. Mexico Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 172. Mexico Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 173. Mexico Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 174. Mexico Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 175. Mexico Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 176. Mexico Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 177. Brazil Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 178. Brazil Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 179. Brazil Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 180. Brazil Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 181. Brazil Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 182. Brazil Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 183. Brazil Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 184. Brazil Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 185. United Kingdom Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 186. United Kingdom Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 187. United Kingdom Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 188. United Kingdom Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 189. United Kingdom Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 190. United Kingdom Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 191. United Kingdom Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 192. United Kingdom Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 193. Germany Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 194. Germany Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 195. Germany Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 196. Germany Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 197. Germany Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 198. Germany Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 199. Germany Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 200. Germany Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 201. France Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 202. France Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 203. France Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 204. France Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 205. France Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 206. France Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 207. France Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 208. France Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 209. Russia Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 210. Russia Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 211. Russia Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 212. Russia Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 213. Russia Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 214. Russia Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 215. Russia Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 216. Russia Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 217. Italy Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 218. Italy Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 219. Italy Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 220. Italy Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 221. Italy Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 222. Italy Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 223. Italy Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 224. Italy Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 225. Spain Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 226. Spain Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 227. Spain Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 228. Spain Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 229. Spain Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 230. Spain Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 231. Spain Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 232. Spain Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 233. China Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 234. China Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 235. China Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 236. China Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 237. China Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 238. China Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 239. China Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 240. China Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 241. India Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 242. India Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 243. India Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 244. India Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 245. India Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 246. India Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 247. India Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 248. India Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 249. Japan Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 250. Japan Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 251. Japan Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 252. Japan Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 253. Japan Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 254. Japan Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 255. Japan Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 256. Japan Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 257. Australia Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 258. Australia Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 259. Australia Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 260. Australia Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 261. Australia Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 262. Australia Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 263. Australia Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 264. Australia Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 265. South Korea Amrinone for Injection Market Size, 2017-2032 (USD Million)
  • TABLE 266. South Korea Amrinone for Injection Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 267. South Korea Amrinone for Injection Market Size, by Lyophilized Powder, 2017-2032 (USD Million)
  • TABLE 268. South Korea Amrinone for Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 269. South Korea Amrinone for Injection Market Size, by Chronic Heart Failure, 2017-2032 (USD Million)
  • TABLE 270. South Korea Amrinone for Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 271. South Korea Amrinone for Injection Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 272. South Korea Amrinone for Injection Market Size, by Specialty Clinics, 2017-2032 (USD Million)
  • TABLE 273. Global Amrinone for Injection Market Share, by Key Player, 2025
  • TABLE 274. Global Amrinone for Injection Market, Key Experts